Videos

Up to one in three people in the Middle East have migraine, with a significant financial, educational and social burden. As Professor Ramez Reda Moustafa explains, easy availability of over-the-counter painkillers means that medication overuse headache is common.   < Previous page

Professor Ramez Reda Moustafa discusses the impact of poor efficacy and tolerability of traditional migraine medicines on treatment adherence, and the benefits of newer migraine-specific therapies that will encourage patients to remain on treatment.     < Previous page

يعاني ما يصل إلى واحد من كل ثلاثة أشخاص في الشرق الأوسط من الصداع النصفي، مما يشكل عبئًا ماليًا وتعليميًا واجتماعيًا كبيرًا. وكما يوضح البروفيسور رامز رضا مصطفى فإن سهولة توفر المسكّنات التي لا تستلزم وصفة طبية يعني أن الصداع الناتج عن الإفراط في تناول الأدوية أمر شائع.   < الصفحة السابقة

يناقش البروفيسور رامز رضا مصطفى تأثير ضعف الفعالية والتحمل لأدوية الصداع النصفي التقليدية على عملية الالتزام بالعلاج، وفوائد العلاجات الجديدة الخاصة بالصداع النصفي (الشقيقة) التي ستشجع المرضى على الاستمرار في العلاج.   < الصفحة السابقة

Professor Fernando Kowacs proposes the type of medical report that is needed to achieve a successful initial application for reimbursement of CGRP monoclonal antibodies for a patient, and how this can be updated for continuing reimbursement success.     < Previous page

O Professor Kowacs propõe o tipo de relatório médico a ser usado para que os pacientes recebam o reembolso de tratamento com anticorpos monoclonais CGRP e como deve ser feita a atualização do relatório.     < Página anterior

Com o aumento do uso dos anticorpos monoclonais CGRP em combinação com outras terapias preventivas, como a onabotulinumtoxinaA, o Professor Kowacs discute as oportunidades para quem sofre de migrânea difícil de tratar.     < Página anterior

As CGRP monoclonal antibodies are increasingly used in combination with other preventive therapies, such as onabotulinumtoxinA, Professor Fernando Kowacs discusses the opportunities for patients with the hardest to treat migraine.     < Previous page

O Professor Fernando Kowacs considera quais pacientes podem se beneficiar dos anticorpos monoclonais CGRP e descreve os fatores que influenciam sua escolha de medicamento para cada paciente, a abordagem de acompanhamento e as estratégias de troca para quem não responde bem a eles.     < Página anterior

Professor Fernando Kowacs considers which patients may benefit from CGRP monoclonal antibodies and describes the factors that influence his choice of drug for individual patients as well as his approach to follow up, and his switching strategies for poor responders.     < Previous page

Há cada vez mais evidências que apoiam a eficácia, a segurança e a tolerabilidade dos anticorpos monoclonais CGRP. O Professor Fernando Kowacs revisa alguns dos principais achados de ensaios clínicos e relata evidências do mundo real publicadas por médicos no Brasil.      < Página anterior

O Professor Fernando Kowacs explica que alguns pacientes esperam anos pelo diagnóstico correto e enfatiza a necessidade de maior disponibilidade de terapias eficazes preventivas e agudas de migrânea, incluindo anticorpos monoclonais CGRP.      < Página anterior

Uma em cada cinco mulheres e um em cada 10 homens sofrem de migrânea no Brasil, com níveis significativos de incapacidade. O Professor Fernando Kowacs discute a prevalência de migrânea no Brasil e os tipos de tratamento disponíveis.      < Página anterior

A growing body of evidence supports the efficacy, safety and tolerability of CGRP monoclonal antibodies. Professor Fernando Kowacs reviews some of the key clinical trial findings and reports real world evidence published by clinicians in Brazil.     < Previous page

Professor Fernando Kowacs explains that some patients wait years before they are correctly diagnosed with migraine, and stresses the need for wider availability of effective preventive and acute migraine therapies, including CGRP monoclonal antibodies.     < Previous page

Approximately one in five women and one in 10 men suffer from migraine in Brazil, with significant levels of disability. Professor Fernando Kowacs discusses the prevalence of migraine in Brazil and the types of treatment available for patients.     < Previous page

As CGRP monoclonal antibodies (mAbs) are rarely 100% effective at preventing migraine, clinicians are starting to combine them with gepants to treat breakthrough headaches. Richard Lipton, Edwin S Lowe Professor of Neurology at the Albert Einstein College of Medicine, New York, USA, explains that there is a growing body of evidence from pharmacokinetic and observational …

For Patricia Pozo-Rosich, 2020 was an important year for patients with migraine, especially in Spain where she works. With access to anti-CGRP therapies becoming available for the first time, neurologists were able to educate their patients about the new agents and start to see the effects in clinical practice. Clinical trial data published in 2020 …

2020 was another momentous year for anti-CGRP therapies.  With the last of the CGRP monoclonal antibodies and the first gepants gaining their first approvals in the USA,1-3 and other anti-CGRP therapies gaining approvals around the world, clinicians have seen a rapid increase in the range of treatments available for their patients with migraine. New clinical …

As clinicians witness a revolution in thinking about migraine and its treatment, Peter Goadsby considers how the future availability of CGRP monoclonal antibodies and small molecule gepants will change the treatment landscape. He welcomes the growing opportunities for patients to be offered individualised treatment that enables them to take back control of their lives.  

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Following the US approval of the first CGRP small molecule receptor antagonist, ubrogepant, for the acute treatment of migraine, Peter Goadsby looks at the potential impact of targeting the CGRP pathway for both prevention and treatment of migraine.

Extensive clinical trial data support the efficacy and safety of anti-CGRP therapies in patients with migraine but there is still much to be learned about their precise role in daily practice. In the first of a series of videos about what comes next for anti-CGRP therapy, Peter Goadsby discusses the challenges that still need to …

The Calcitonin Gene-Related Peptide (CGRP) Forum has been established by an international group of clinicians and researchers. It provides all healthcare professionals with open and free access to independent news, information, comment and resources about the exciting potential of CGRP as a novel therapeutic target for the prevention of migraine in millions of people worldwide.

Multiple lines of evidence support a role for CGRP in migraine pathophysiology. Its blockade is now a potentially important therapeutic target for migraine prevention.